BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiocchi C. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol. 2015;30 Suppl 1:12-18. [PMID: 25827798 DOI: 10.1111/jgh.12751] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
2 Godskesen LE, Lassen TR, Jespersen NR, Siersbæk M, Yan Y, Nielsen MM, Tjønnfjord SK, Grøntved L, Madsen G, Kjems J, Bøtker HE, Schmidt MR, Krag A, Kjeldsen J. Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial. Sci Rep 2020;10:9537. [PMID: 32533085 DOI: 10.1038/s41598-020-65692-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Regueiro M, Strong SA, Ferrari L, Fichera A. Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies. J Gastrointest Surg 2016;20:1415-20. [PMID: 27230995 DOI: 10.1007/s11605-016-3172-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Banasik J, Padysz M, Pawłowicz M, Gąsiorowska A. Does the location of inflammatory lesions in the gastrointestinal tract determine the clinical course of Crohn’s disease? Postępy Higieny i Medycyny Doświadczalnej 2021;75:12-7. [DOI: 10.5604/01.3001.0014.6581] [Reference Citation Analysis]
5 MacLellan A, Moore-Connors J, Grant S, Cahill L, Langille MGI, Van Limbergen J. The Impact of Exclusive Enteral Nutrition (EEN) on the Gut Microbiome in Crohn's Disease: A Review. Nutrients 2017;9:E0447. [PMID: 28468301 DOI: 10.3390/nu9050447] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
6 Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:929-42. [PMID: 29330783 DOI: 10.1007/s40262-017-0627-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
7 Kim N, Lertnimitphun P, Jiang Y, Tan H, Zhou H, Lu Y, Xu H. Andrographolide inhibits inflammatory responses in LPS-stimulated macrophages and murine acute colitis through activating AMPK. Biochemical Pharmacology 2019;170:113646. [DOI: 10.1016/j.bcp.2019.113646] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
8 Hu Q, Ren J, Li G, Wu X, Li J. The Impact of Obesity on the Clinical Course of Inflammatory Bowel Disease: A Meta-Analysis. Med Sci Monit. 2017;23:2599-2606. [PMID: 28552901 DOI: 10.12659/msm.901969] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
9 Neubauer K, Woźniak-Stolarska B, Krzystek-Korpacka M. Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results. Biomed Res Int 2018;2018:4961753. [PMID: 30515402 DOI: 10.1155/2018/4961753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Sinh P, Cross R. Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1107-15. [PMID: 32978937 DOI: 10.1093/ibd/izaa258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Huang J, Chen T, Liu Y, Lyu L, Li X, Yue W. How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)? Turk J Gastroenterol 2019;30:132-8. [PMID: 30429108 DOI: 10.5152/tjg.2018.17828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Palmieri O, Mazza T, Castellana S, Panza A, Latiano T, Corritore G, Andriulli A, Latiano A. Inflammatory Bowel Disease Meets Systems Biology: A Multi-Omics Challenge and Frontier. OMICS 2016;20:692-8. [PMID: 27930092 DOI: 10.1089/omi.2016.0147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
13 Joshi M, Reddy ND, Kumar N, Sumalatha S, Chamallamudi MR. Cinnamyl Sulfonamide Hydroxamate Derivatives Inhibited LPS-Stimulated NF-kB Expression in RAW 264.7 Cells In Vitro and Mitigated Experimental Colitis in Wistar Rats In Vivo. Curr Pharm Des 2020;26:4934-43. [PMID: 32586247 DOI: 10.2174/1381612826666200625101442] [Reference Citation Analysis]
14 Bodini G, Giuliana E, Giberti I, Guarona G, Benvenuto F, Ferretti E, Demarzo MG, Da Rin G, Icardi G, Giannini EG. Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. Gastrointestinal Disorders 2022;4:77-83. [DOI: 10.3390/gidisord4020009] [Reference Citation Analysis]
15 Chang S, Parker GA, Kleinschmidt SE, Olsen GW, Ley CA, Taiwo OA. A Pathology Review of the Lower Gastrointestinal Tract in Relation to Ulcerative Colitis in Rats and Cynomolgus Macaques Treated With Ammonium Perfluorooctanoate. Toxicol Pathol 2020;48:593-602. [PMID: 32186254 DOI: 10.1177/0192623320911606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Mannon PJ. Immunological Diseases of the Gastrointestinal Tract. Clinical Immunology. Elsevier; 2019. pp. 1005-1019.e1. [DOI: 10.1016/b978-0-7020-6896-6.00075-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Shukla A, Surapaneni S, Sobel JD. Desquamative Inflammatory Vaginitis as an Extraintestinal Manifestation of Crohn’s Disease. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00733-y] [Reference Citation Analysis]
18 Dragasevic S, Stankovic B, Milosavljevic T, Sokic-Milutinovic A, Lukic S, Alempijevic T, Zukic B, Kotur N, Nikcevic G, Pavlovic S, Popovic D. Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2017;29:909-15. [PMID: 28452812 DOI: 10.1097/MEG.0000000000000877] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Mehrtash F. Sustained Crohn’s Disease Remission with an Exclusive Elemental and Exclusion Diet: A Case Report. GastrointestDisord 2021;3:129-38. [DOI: 10.3390/gidisord3030014] [Reference Citation Analysis]
20 Wędrychowicz A, Zając A, Tomasik P. Advances in nutritional therapy in inflammatory bowel diseases: Review. World J Gastroenterol 2016; 22(3): 1045-1066 [PMID: 26811646 DOI: 10.3748/wjg.v22.i3.1045] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 45] [Article Influence: 9.7] [Reference Citation Analysis]
21 Principi M, Losurdo G, Iannone A, Contaldo A, Deflorio V, Ranaldo N, Pisani A, Ierardi E, Di Leo A, Barone M. Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population. Ann Gastroenterol. 2018;31:469-473. [PMID: 29991892 DOI: 10.20524/aog.2018.0273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
22 Rahman M, Kumar V, Beg S, Sharma G, Katare OP, Anwar F. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artif Cells Nanomed Biotechnol 2016;44:1597-608. [PMID: 26758815 DOI: 10.3109/21691401.2015.1129617] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
23 Tegtmeyer D, Seidl M, Gerner P, Baumann U, Klemann C. Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatr Allergy Immunol 2017;28:412-29. [DOI: 10.1111/pai.12734] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
24 Vanuytsel T, Tack J, Farre R. The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation. Front Nutr 2021;8:717925. [PMID: 34513903 DOI: 10.3389/fnut.2021.717925] [Reference Citation Analysis]
25 Li XX, Liu Y, Luo J, Huang ZD, Zhang C, Fu Y. Vitamin D deficiency associated with Crohn's disease and ulcerative colitis: a meta-analysis of 55 observational studies. J Transl Med 2019;17:323. [PMID: 31547829 DOI: 10.1186/s12967-019-2070-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Danese S, Peyrin-Biroulet L. Evolution of IL-23 Blockade in Inflammatory Bowel Disease. J Crohns Colitis 2022;16:ii1-2. [PMID: 35553668 DOI: 10.1093/ecco-jcc/jjab188] [Reference Citation Analysis]
27 Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. Intest Res 2020;18:45-55. [PMID: 32013314 DOI: 10.5217/ir.2019.00039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Debebe T, Krüger M, Huse K, Kacza J, Mühlberg K, König B, Birkenmeier G. Ethyl Pyruvate: An Anti-Microbial Agent that Selectively Targets Pathobionts and Biofilms. PLoS One 2016;11:e0162919. [PMID: 27658257 DOI: 10.1371/journal.pone.0162919] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Frapaise FX. The End of Phase 3 Clinical Trials in Biosimilars Development? BioDrugs 2018;32:319-24. [PMID: 29943088 DOI: 10.1007/s40259-018-0287-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
30 Rahimian R, Zirak MR, Keshavarz M, Fakhraei N, Mohammadi-farani A, Hamdi H, Mousavizadeh K. Involvement of PPAR γ in the protective action of tropisetron in an experimental model of ulcerative colitis. Immunopharmacology and Immunotoxicology 2016;38:432-40. [DOI: 10.1080/08923973.2016.1231202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
31 Neubauer K, Bednarz-Misa I, Walecka-Zacharska E, Wierzbicki J, Agrawal A, Gamian A, Krzystek-Korpacka M. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. Int J Mol Sci. 2019;20. [PMID: 30621173 DOI: 10.3390/ijms20010166] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
32 Gîlcă-Blanariu GE, Diaconescu S, Ciocoiu M, Ștefănescu G. New Insights into the Role of Trace Elements in IBD. Biomed Res Int 2018;2018:1813047. [PMID: 30258848 DOI: 10.1155/2018/1813047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
33 Sherkat R, Rostami S, Yaran M, Emami MH, Saneian H, Tavakoli H, Adibi P, Behnam M, Sheykhbahaei S, Bagherpour B, Khoshnevisan R, Najafi S. Establishment and Development of the First Biobank of Inflammatory Bowel Disease, Suspected to Primary Immunodeficiency Diseases in Iran. Adv Biomed Res 2018;7:45. [PMID: 29657930 DOI: 10.4103/abr.abr_278_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 van Herk EH, Te Velde AA. Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets. J Gastroenterol Hepatol 2016;31:1393-404. [PMID: 26990130 DOI: 10.1111/jgh.13342] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
35 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
36 Wang YN, Meng XC, Dong YF, Zhao XH, Qian JM, Wang HY, Li JN. Effects of probiotics and prebiotics on intestinal microbiota in mice with acute colitis based on 16S rRNA gene sequencing. Chin Med J (Engl) 2019;132:1833-42. [PMID: 31268903 DOI: 10.1097/CM9.0000000000000308] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
37 Hendrickx JO, van Gastel J, Leysen H, Martin B, Maudsley S. High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases. Pharmacol Rev 2020;72:191-217. [PMID: 31843941 DOI: 10.1124/pr.119.017921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 de Castro MM, Corona LP, Pascoal LB, Miyamoto JÉ, Ignacio-Souza LM, de Lourdes Setsuko Ayrizono M, Torsoni MA, Torsoni AS, Leal RF, Milanski M. Dietary Patterns Associated to Clinical Aspects in Crohn's Disease Patients. Sci Rep 2020;10:7033. [PMID: 32341416 DOI: 10.1038/s41598-020-64024-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 de Souza HSP, Fiocchi C. Network Medicine: A Mandatory Next Step for Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:671-9. [PMID: 29562278 DOI: 10.1093/ibd/izx111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
40 Carbone F, Bodini G, Brunacci M, Bonaventura A, Vecchiè A, Liberale L, Crespi M, Baldissarro I, Dallegri F, Savarino V, Montecucco F, Giannini EG. Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. Eur J Clin Invest 2018;48:e13002. [PMID: 30011062 DOI: 10.1111/eci.13002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
41 Garber A, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. Curr Gastroenterol Rep. 2019;21:31. [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
42 Dore MP, Rocchi C, Longo NP, Scanu AM, Vidili G, Padedda F, Pes GM. Effect of Probiotic Use on Adverse Events in Adult Patients with Inflammatory Bowel Disease: a Retrospective Cohort Study. Probiotics Antimicrob Proteins 2020;12:152-9. [PMID: 30685823 DOI: 10.1007/s12602-019-9517-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]